The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and ...

Eli Lilly and Company (NYSE: LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly ...

Feb 18 (Reuters) - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ...

Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with ...

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b ...

Researchers identified multiple gene signatures linked to psoriasis severity, body weight, and immune activity. These ...

Psoriasis is a common inflammatory skin disease linked to several long-term health conditions, such as heart disease, arthritis and type 2 diabetes, and has a substantial impact on sufferers' quality ...

Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her symptoms, you know that the skin condition is far from glamorous and ...

"Understanding biologic therapy trajectories in Medicaid is important, given its distinct formulary restrictions and patient demographics," they concluded. "Interventions must not only address access ...